Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Sangamo Therapeutics (SGMO)

Sangamo Therapeutics (SGMO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 143,010
  • Shares Outstanding, K 336,495
  • Annual Sales, $ 57,800 K
  • Annual Income, $ -97,940 K
  • EBIT $ -109 M
  • EBITDA $ -100 M
  • 60-Month Beta 1.41
  • Price/Sales 2.59
  • Price/Cash Flow N/A
  • Price/Book 21.51
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.44
  • Most Recent Earnings $-0.11 on 11/06/25
  • Next Earnings Date 03/16/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 169.52% (-49.61%)
  • Historical Volatility 83.75%
  • IV Percentile 34%
  • IV Rank 21.49%
  • IV High 467.09% on 05/05/25
  • IV Low 88.05% on 07/14/25
  • Expected Move (DTE 19) 0.1360 (32.00%)
  • Put/Call Vol Ratio 0.56
  • Today's Volume 1,279
  • Volume Avg (30-Day) 1,329
  • Put/Call OI Ratio 0.30
  • Today's Open Interest 96,980
  • Open Int (30-Day) 99,858
  • Expected Range 0.2890 to 0.5610

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.01
  • Number of Estimates 1
  • High Estimate 0.01
  • Low Estimate 0.01
  • Prior Year -0.11
  • Growth Rate Est. (year over year) +109.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4200 +1.19%
on 12/26/25
0.5466 -22.25%
on 12/04/25
-0.0391 (-8.42%)
since 11/26/25
3-Month
0.3846 +10.50%
on 11/20/25
0.7660 -44.52%
on 09/29/25
-0.2390 (-35.99%)
since 09/26/25
52-Week
0.3846 +10.50%
on 11/20/25
2.7300 -84.43%
on 12/27/24
-2.2050 (-83.84%)
since 12/26/24

Most Recent Stories

More News
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease

STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has...

SGMO : 0.4250 (-4.49%)
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy

RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted...

SGMO : 0.4250 (-4.49%)
Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease

RICHMOND, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has accepted...

SGMO : 0.4250 (-4.49%)
Sangamo: Q3 Earnings Snapshot

Sangamo: Q3 Earnings Snapshot

SGMO : 0.4250 (-4.49%)
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results

Held meeting with U.S. Food and Drug Administration (FDA) where, among other things, they reiterated October 2024 agreement to use estimated glomerular filtration rate (eGFR) slope as an endpoint to support...

SGMO : 0.4250 (-4.49%)
Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call

RICHMOND, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the company has scheduled the release of its third quarter...

SGMO : 0.4250 (-4.49%)
Sangamo: Q2 Earnings Snapshot

Sangamo: Q2 Earnings Snapshot

SGMO : 0.4250 (-4.49%)
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

Announced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients...

SGMO : 0.4250 (-4.49%)
Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

RICHMOND, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its second quarter...

SGMO : 0.4250 (-4.49%)
RFK Jr. Just Supercharged These 2 Biotech Penny Stocks

SGMO and EDIT are set to benefit from RFK Jr.’s plans to fast-track the review of drugs targeting rare diseases.

SGMO : 0.4250 (-4.49%)
LLY : 1,077.75 (+0.07%)
EDIT : 2.17 (-1.81%)

Business Summary

Sangamo Therapeutics, Inc. is a biotechnology company. It focuses on research and development of genomic therapies as well as develops medicines for patient with genetic diseases. The Company's product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Sangamo Therapeutics Inc.,...

See More

Key Turning Points

3rd Resistance Point 0.4598
2nd Resistance Point 0.4509
1st Resistance Point 0.4379
Last Price 0.4250
1st Support Level 0.4160
2nd Support Level 0.4071
3rd Support Level 0.3941

See More

52-Week High 2.7300
Fibonacci 61.8% 1.8341
Fibonacci 50% 1.5573
Fibonacci 38.2% 1.2805
Last Price 0.4250
52-Week Low 0.3846

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar